Jeil Pharma's new OAB treatment ‘vibegron’ nears release
By Kim, Jin-Gu | translator Alice Kang
21.06.14 17:56:39
가나다라
0
In addition to completing Phase I trial for domestic manufacturing, patient enrollment for the bridging study is near complete
May be released within this year at earliest… whether it will rise as a rival to the market leading Betmiga gains attention
▲Vibegron product that is being sold by Kyorin Pharmaceutical
‘Vibegron,' a new drug indicated for the treatment of overactive bladder (OAB) that Jeil Pharmaceutical acquired a domestic license for from Kyorin Pharmaceutical, is soon to be approved in Korea.Two clinical trials related to the domestic approval and manufacturing of Vibegron have been completed or are near completion. At the earliest, it is expected that the drug may be released within this year.
According to industry sources on the 14th, Jeil Pharmaceutical had recently completed its Phase I clinical trial on vibegron. The trial investigated the safety and pharmacokinetics of JLP-2002 in comparison with the original drug.
The trial was conducted for the purpose of
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)